A recently published review has focused on the evolution of treatment landscape of hemophilia...
Read More
The longest life expectancy makes hemophiliacs susceptible to diseases not related to haemophilia and...
Emicizumab represents a therapeutic innovation not only for haemophiliacs A with inhibitor but also...
Current standard therapy for severe hemophilia A is regular infusions of either plasma-derived or...
Patients affected by severe hemophilia A and B must be treated with plasmaderived or...
The most important and prevalent inherited bleeding disorders are hemophilia A and B, rare...
ACE910 is a recombinant humanized bispecific antibody that binds to activated factor IX and...